This website is for Healthcare Professionals only.
TEPKINLY is the first-and-only subcutaneous bispecific antibody treatment for 3L+ diffuse large B-cell lymphoma (DLBCL)1
TEPKINLY as monotherapy is indicated for the treatment of adult patients with relapsed or refractory DLBCL after 2 or more lines of systemic therapy.1
3L+=third-line plus.
Offer your patients a chance at deep and durable responses and long-term survival1-3*
- 62% ORR
- 39% CR
- mDOR of 15.5 months
- mOS of 19.4 months
*The median follow-up time was 10.7 months (range: 0.3-17.9 months) and the mean follow-up for mOS was 20 months (range: 0.3+-28.2 months). ORR: 62% (95% CI, 53.3-70); CR: 39% (95% CI, 30.7-47.5); mDOR: 15.5 months (95% CI, 9.7-NR); overall survival (OS) was a secondary endpoint in the study. After a median follow-up time of 20 months (range: 0.3+-28.2 months), the mOS for patients on TEPKINLY was 19.4 months (11.7-NR).
CI=confidence interval; CR=complete response; mDOR=median duration of response; mOS=median overall survival; NR=not reached; ORR=overall response rate; SmPC=Summary of Product Characteristics.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
This medicinal product has been authorised under a ‘conditional approval’. This means that further evidence on this medicinal product is awaited. The European Medicines Agency will review new information on this medicinal product frequently and the SmPC will be updated as necessary.
Please see the TEPKINLY SmPC for Full Prescribing and Safety Information.
[INCLUDE SAFETY INFORMATION PER LOCAL REGULATIONS]
I would like to request a meeting with an AbbVie representative.
Learn what TEPKINLY could offer your patients.
TEPKINLY as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after 2 or more lines of systemic therapy.1
References: 1. TEPKINLY Summary of Product Characteristics. AbbVie Inc. 2. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. 2021;398(10306):1157-1169. doi:10.1200/JCO.22.01725 3. Jurczak W, Ghesquieres W, Karimi Y, et al. Longer follow-up from the pivotal EPCORE NHL-1 trial reaffirms subcutaneous epcoritamab induces deep, durable complete remissions In patients with relapsed/refractory large B-cell lymphoma. Hemasphere. 2023;7(suppl):e081065c. doi:10.1097/01.HS9.0000971368.08106.5c
ALL-EPCOR-230034